| Report ID | Date of report | Patient age | Patient gender |
| 135076 | Jan, 16, 2006 | 76 | Female |
List of drugs the patient takes:
| Drug | Ingredient(s) |
Gleevec | imatinib mesylate |
Aspegic 1000 | insulin glulisine recombinant |
| Name |
Asthenia |
Cerebral Disorder |
Diplopia |
Dysphagia |
Dysphonia |
Eaton-lambert Syndrome |
Electromyogram Abnormal |
Muscular Weakness |
Myasthenic Syndrome |
Neuroendocrine Carcinoma Of The Skin |
Paraneoplastic Syndrome |
Speech Disorder |
Results from eHealthMe : 8 report(s)
Comparison with the patient:
| Name | Count (% of total reports) |
Asthenia | 2 (25.00%) |
Cerebral Disorder | 4 (50.00%) |
Diplopia | 4 (50.00%) |
Dysphagia | 4 (50.00%) |
Dysphonia | 4 (50.00%) |
Eaton-lambert Syndrome | 4 (50.00%) |
Electromyogram Abnormal | 4 (50.00%) |
Muscular Weakness | 4 (50.00%) |
Myasthenic Syndrome | 2 (25.00%) |
Neuroendocrine Carcinoma Of The Skin | 4 (50.00%) |
Paraneoplastic Syndrome | 2 (25.00%) |
Speech Disorder | 4 (50.00%) |
Top 3 (total: 10. Click here to see more) co-used drugs - potential interacting drugs:
| Name | Count (% of total co-drugs) |
Tazocilline (piperacillin Sodium, Tazobactam Sodium) | 3 (6.67%) |
Gentamicin | 3 (6.67%) |
Bactrin (sulfamethoxazole) | 3 (6.67%) |
Death reported: 0
| Name | Count (% of total reports) |
Muscular Weakness | 4 (50.00%) |
Neuroendocrine Carcinoma Of The Skin | 4 (50.00%) |
Speech Disorder | 4 (50.00%) |
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Recent drug risk analysis reports:
